{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T02:46:40Z","timestamp":1789958800611,"version":"4.0.1"},"reference-count":25,"publisher":"Wiley","issue":"11","license":[{"start":{"date-parts":[[2010,3,29]],"date-time":"2010-03-29T00:00:00Z","timestamp":1269820800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer"],"published-print":{"date-parts":[[2010,6]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>BACKGROUND:<\/jats:title><jats:p>Clonal evolution is frequently detected in patients developing resistance to imatinib. The outcome of patients with clonal evolution treated with second generation tyrosine kinase inhibitors is not known.<\/jats:p><\/jats:sec><jats:sec><jats:title>METHODS:<\/jats:title><jats:p>The authors analyzed the outcome of 177 CML patients after second tyrosine kinase inhibitor therapy.<\/jats:p><\/jats:sec><jats:sec><jats:title>RESULTS:<\/jats:title><jats:p>Ninety\u2010five patients were in chronic phase, 30 had clonal evolution, 28 were in accelerated phase (AP), and 24 were in AP plus clonal evolution. Major cytogenetic response rates were 58%, 54%, 28%, and 13%; 2\u2010year overall survival (OS) rates were 86%, 73%, 68%, and 33%; and 2\u2010year event\u2010free survival (EFS) rates were 69%, 67%, 31%, and 8%, respectively. The hematologic and cytogenetic response rates, OS, and EFS were no different between patients in chronic phase with clonal evolution and patients with chronic phase and no clonal evolution. However, clonal evolution had a significant adverse impact when associated with other features of AP. On multivariate analysis, clonal evolution had no independently significant effect on achieving major cytogenetic response on the second generation tyrosine kinase inhibitors. The factors predicting increasing major cytogenetic response to second generation tyrosine kinase inhibitors were prior achievement of major cytogenetic response with imatinib, higher hemoglobin levels, no splenomegaly, lower percentage of Philadelphia chromosome\u2010positive metaphases, and no prior chemotherapy.<\/jats:p><\/jats:sec><jats:sec><jats:title>CONCLUSIONS:<\/jats:title><jats:p>Clonal evolution constitutes a heterogeneous entity with variable outcome with second generation tyrosine kinase inhibitors, with trisomy 8, chromosome 17, and complex abnormalities having the worst outcome, regardless of the number of metaphases involved. The molecular events behind these abnormalities and potential therapeutic approaches directed at them need to be defined. Cancer 2010. \u00a9 2010 American Cancer Society.<\/jats:p><\/jats:sec>","DOI":"10.1002\/cncr.25015","type":"journal-article","created":{"date-parts":[[2010,3,29]],"date-time":"2010-03-29T11:35:01Z","timestamp":1269862501000},"page":"2673-2681","source":"Crossref","is-referenced-by-count":46,"title":["Survival outcomes for clonal evolution in chronic myeloid leukemia patients on second generation tyrosine kinase inhibitor therapy"],"prefix":"10.1002","volume":"116","author":[{"given":"Dushyant","family":"Verma","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hagop","family":"Kantarjian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianqin","family":"Shan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan","family":"O'Brien","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zeev","family":"Estrov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guillermo","family":"Garcia\u2010Manero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles","family":"Koller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gautam","family":"Borthakur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorge","family":"Cortes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2010,3,29]]},"reference":[{"key":"e_1_2_6_2_2","doi-asserted-by":"publisher","DOI":"10.4065\/81.7.973"},{"key":"e_1_2_6_3_2","first-page":"628","article-title":"The relationship between secondary chromosomal abnormalities and blast transformation in chronic myelogenous leukemia","volume":"9","author":"Anastasi J","year":"1995","journal-title":"Leukemia."},{"key":"e_1_2_6_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.hoc.2004.03.012"},{"key":"e_1_2_6_5_2","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.11064"},{"key":"e_1_2_6_6_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-09-2790"},{"key":"e_1_2_6_7_2","first-page":"260","article-title":"Chronic myeloid leukemia in chronic phase responding to imatinib: the occurrence of additional cytogenetic abnormalities predicts disease progression","volume":"88","author":"Marktel S","year":"2003","journal-title":"Haematologica."},{"key":"e_1_2_6_8_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-03-0777"},{"key":"e_1_2_6_9_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1998.16.10.3279"},{"key":"e_1_2_6_10_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1996.14.1.196"},{"key":"e_1_2_6_11_2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19880401)61:7<1441::AID-CNCR2820610727>3.0.CO;2-C"},{"key":"e_1_2_6_12_2","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1182\/blood.V72.1.294.294","article-title":"Prognostic significance of additional cytogenetic abnormalities at diagnosis of Philadelphia chromosome\u2010positive chronic granulocytic leukemia","volume":"72","author":"Sokal JE","year":"1988","journal-title":"Blood."},{"key":"e_1_2_6_13_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V84.12.4368.bloodjournal84124368"},{"key":"e_1_2_6_14_2","first-page":"113","article-title":"Prognostic significance of cytogenetic abnormalities in patients with chronic myelogenous leukemia","volume":"3","author":"Przepiorka D","year":"1988","journal-title":"Bone Marrow Transplant."},{"key":"e_1_2_6_15_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1992.10.5.772"},{"key":"e_1_2_6_16_2","first-page":"121","article-title":"Cytogenetic characterization and proteomic profiling of the imatinib\u2010resistant cell line KCL22\u2010R","volume":"31","author":"Rosenhahn J","year":"2007","journal-title":"Int J Oncol."},{"key":"e_1_2_6_17_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.20922"},{"key":"e_1_2_6_18_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2402741"},{"key":"e_1_2_6_19_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-09-046839"},{"key":"e_1_2_6_20_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa055104"},{"key":"e_1_2_6_21_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-04-2139"},{"key":"e_1_2_6_22_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V99.6.1928"},{"key":"e_1_2_6_23_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa011573"},{"key":"e_1_2_6_24_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.21979"},{"key":"e_1_2_6_25_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2404318"},{"key":"e_1_2_6_26_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.onc.1206087"}],"container-title":["Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fcncr.25015","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cncr.25015","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T12:42:05Z","timestamp":1760272925000},"score":1,"resource":{"primary":{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/10.1002\/cncr.25015"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,3,29]]},"references-count":25,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2010,6]]}},"alternative-id":["10.1002\/cncr.25015"],"URL":"https:\/\/doi.org\/10.1002\/cncr.25015","archive":["Portico"],"relation":{},"ISSN":["0008-543X","1097-0142"],"issn-type":[{"value":"0008-543X","type":"print"},{"value":"1097-0142","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,3,29]]}}}